temozolomide has been researched along with Bone Cancer in 22 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a case of anaplastic oligodendroglioma metastatic to bone with a dramatic and durable response to temozolomide therapy." | 8.82 | Bony metastases of anaplastic oligodendroglioma respond to temozolomide. ( Bilbao, JM; Morrison, T; Perry, JR; Yang, G, 2004) |
| "The goal of the research was to investigate if a combination of vincristine, irinotecan and temozolomide (VIT) could benefit adult patients with metastatic Ewing sarcoma who had already been heavily pretreated." | 8.31 | Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma. ( Ahmed, MA; Basaran, M; Dogan, I; Iribas, A, 2023) |
| "Irinotecan and temozolomide (IT) is a widely used regimen for relapsed Ewing sarcoma (ES), although studies are largely limited to paediatric populations." | 8.02 | Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma. ( Abuhijla, F; Abuhijlih, R; Alnsour, A; Halalsheh, H; Ismail, T; Khozouz, O; Lewin, J; Salah, S; Shahin, O; Sultan, I; To, YH; Yaser, S, 2021) |
| "Temozolomide/etoposide is a feasible candidate as salvage therapy for relapsed osteosarcoma." | 5.56 | Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma. ( Adachi, S; Akazawa, R; Arakawa, Y; Hiramatsu, H; Kato, I; Moritake, H; Okamoto, T; Saida, S; Sakamoto, A; Sumiyoshi, S; Takita, J; Umeda, K, 2020) |
| "We report a case of anaplastic oligodendroglioma metastatic to bone with a dramatic and durable response to temozolomide therapy." | 4.82 | Bony metastases of anaplastic oligodendroglioma respond to temozolomide. ( Bilbao, JM; Morrison, T; Perry, JR; Yang, G, 2004) |
| "The goal of the research was to investigate if a combination of vincristine, irinotecan and temozolomide (VIT) could benefit adult patients with metastatic Ewing sarcoma who had already been heavily pretreated." | 4.31 | Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma. ( Ahmed, MA; Basaran, M; Dogan, I; Iribas, A, 2023) |
| "Irinotecan and temozolomide (IT) is a widely used regimen for relapsed Ewing sarcoma (ES), although studies are largely limited to paediatric populations." | 4.02 | Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma. ( Abuhijla, F; Abuhijlih, R; Alnsour, A; Halalsheh, H; Ismail, T; Khozouz, O; Lewin, J; Salah, S; Shahin, O; Sultan, I; To, YH; Yaser, S, 2021) |
| "In heavily pretreated patients with refractory/relapsed solid tumors, the vincristine, irinotecan, and temozolomide regimen seemed promising in Ewing sarcoma patients and was well tolerated." | 3.91 | Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience. ( Büyükkapu Bay, S; Çakır, FB; Darendeliler, E; Görgün, O; Kebudi, R; Zülfikar, B, 2019) |
| "In vitro talazoparib potentiated the toxicity of temozolomide up to 85-fold, with marked potentiation in Ewing sarcoma and leukemia lines (30-50-fold)." | 3.81 | Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. ( Billups, CA; Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Kurmasheva, RT; Lock, RB; Lyalin, D; Maris, JM; Reynolds, CP; Smith, MA, 2015) |
| "We conducted a phase I and pharmacokinetic study of the epidermal growth factor receptor (EGFR) inhibitor erlotinib as a single agent and in combination with temozolomide in children with refractory solid tumors." | 2.73 | Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. ( Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD, 2008) |
| "A case of anaplastic oligodendroglioma with femoral metastasis is presented in a 37-year old male with a 2-year history of progressive headaches and dizziness associated with a 2-month history of epilepsy and right hemiparesis." | 2.47 | Extracranial skeletal metastasis in anaplastic oligodendroglioma: case report and review of the literature. ( Liu, B; Qu, L; Tao, H; Wu, Y, 2011) |
| "As long as metastasis is confined to one organ system and is removable, surgery remains the treatment of first choice." | 2.42 | [Therapy of malignant melanoma at the stage of distant metastasis]. ( Eigentler, TK; Garbe, C, 2004) |
| "Temozolomide/etoposide is a feasible candidate as salvage therapy for relapsed osteosarcoma." | 1.56 | Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma. ( Adachi, S; Akazawa, R; Arakawa, Y; Hiramatsu, H; Kato, I; Moritake, H; Okamoto, T; Saida, S; Sakamoto, A; Sumiyoshi, S; Takita, J; Umeda, K, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 7 (31.82) | 2.80 |
| Authors | Studies |
|---|---|
| Umeda, K | 2 |
| Taura, K | 1 |
| Kato, I | 2 |
| Saida, S | 2 |
| Hiramatsu, H | 2 |
| Shimizu, H | 1 |
| Nakamoto, Y | 1 |
| Uto, M | 1 |
| Mizowaki, T | 1 |
| Sakamoto, A | 2 |
| Adachi, S | 2 |
| Okamoto, T | 2 |
| Takita, J | 2 |
| Dogan, I | 1 |
| Iribas, A | 1 |
| Ahmed, MA | 1 |
| Basaran, M | 1 |
| Yi, GZ | 1 |
| Zhu, TC | 1 |
| Que, TS | 1 |
| Li, ZY | 1 |
| Huang, GL | 1 |
| Palubeckaitė, I | 1 |
| Venneker, S | 1 |
| van den Akker, BEWM | 1 |
| Briaire-de Bruijn, IH | 1 |
| Boveé, JVMG | 1 |
| Akazawa, R | 1 |
| Arakawa, Y | 1 |
| Sumiyoshi, S | 1 |
| Moritake, H | 1 |
| Salah, S | 1 |
| To, YH | 1 |
| Khozouz, O | 1 |
| Ismail, T | 1 |
| Yaser, S | 1 |
| Alnsour, A | 1 |
| Shahin, O | 1 |
| Sultan, I | 1 |
| Abuhijlih, R | 1 |
| Halalsheh, H | 1 |
| Abuhijla, F | 1 |
| Lewin, J | 1 |
| Ju, HY | 1 |
| Park, M | 1 |
| Lee, JA | 1 |
| Park, HJ | 1 |
| Park, SY | 1 |
| Kim, JH | 1 |
| Kang, HG | 1 |
| Yang, HC | 1 |
| Park, BK | 1 |
| Naviglio, S | 1 |
| Rabusin, M | 1 |
| Büyükkapu Bay, S | 1 |
| Kebudi, R | 1 |
| Görgün, O | 1 |
| Zülfikar, B | 1 |
| Darendeliler, E | 1 |
| Çakır, FB | 1 |
| Bazan, F | 1 |
| Vollmer, I | 1 |
| Gayete, A | 1 |
| Sha, SJ | 1 |
| Wu, HP | 1 |
| Lu, K | 1 |
| Chen, HJ | 1 |
| Huang, PH | 1 |
| Huang, SH | 1 |
| Hsu, CT | 1 |
| Leccia, MT | 1 |
| Planchamp, F | 1 |
| Sassolas, B | 1 |
| Combemale, P | 1 |
| Modiano, P | 1 |
| Bedane, C | 1 |
| Cupissol, D | 1 |
| Derrey, S | 1 |
| Dygai-Cochet, I | 1 |
| Lamant, L | 1 |
| Lubrano, V | 1 |
| Mirabel, X | 1 |
| Mourrégot, A | 1 |
| Rougé Bugat, ME | 1 |
| Siegrist, S | 1 |
| Thariat, J | 1 |
| Tiffet, O | 1 |
| Truc, G | 1 |
| Verdoni, L | 1 |
| Mazeau-Woynar, V | 1 |
| Smith, MA | 1 |
| Reynolds, CP | 1 |
| Kang, MH | 1 |
| Kolb, EA | 1 |
| Gorlick, R | 1 |
| Carol, H | 1 |
| Lock, RB | 1 |
| Keir, ST | 1 |
| Maris, JM | 1 |
| Billups, CA | 1 |
| Lyalin, D | 1 |
| Kurmasheva, RT | 1 |
| Houghton, PJ | 1 |
| Bonney, PA | 1 |
| Santucci, JA | 1 |
| Maurer, AJ | 1 |
| Sughrue, ME | 1 |
| McNall-Knapp, RY | 2 |
| Battiste, JD | 1 |
| Kamiya-Matsuoka, C | 1 |
| Cachia, D | 1 |
| Waguespack, SG | 1 |
| Crane, CH | 1 |
| Mahajan, A | 1 |
| Brown, PD | 1 |
| Nam, JY | 1 |
| McCutcheon, IE | 1 |
| Penas-Prado, M | 1 |
| Jakacki, RI | 1 |
| Hamilton, M | 1 |
| Gilbertson, RJ | 1 |
| Blaney, SM | 1 |
| Tersak, J | 1 |
| Krailo, MD | 1 |
| Ingle, AM | 1 |
| Voss, SD | 1 |
| Dancey, JE | 1 |
| Adamson, PC | 1 |
| Wu, Y | 1 |
| Liu, B | 1 |
| Qu, L | 1 |
| Tao, H | 1 |
| Kanold, J | 1 |
| Paillard, C | 1 |
| Tchirkov, A | 1 |
| Lang, P | 1 |
| Kelly, A | 1 |
| Halle, P | 1 |
| Isfan, F | 1 |
| Merlin, E | 1 |
| Marabelle, A | 1 |
| Rochette, E | 1 |
| Deméocq, F | 1 |
| Morrison, T | 1 |
| Bilbao, JM | 1 |
| Yang, G | 1 |
| Perry, JR | 1 |
| Garbe, C | 1 |
| Eigentler, TK | 1 |
| Aksoy, S | 1 |
| Abali, H | 1 |
| Kiliçkap, S | 1 |
| Güler, N | 1 |
| Wagner, LM | 1 |
| McAllister, N | 1 |
| Goldsby, RE | 1 |
| Rausen, AR | 1 |
| McCarville, MB | 1 |
| Albritton, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for temozolomide and Bone Cancer
| Article | Year |
|---|---|
Extracranial skeletal metastasis in anaplastic oligodendroglioma: case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Dacarbazine; Femur; Humans; Magnetic Reson | 2011 |
Bony metastases of anaplastic oligodendroglioma respond to temozolomide.
Topics: Adult; Bone Neoplasms; Dacarbazine; Humans; Male; Oligodendroglioma; Retrospective Studies; Temozolo | 2004 |
[Therapy of malignant melanoma at the stage of distant metastasis].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2004 |
1 trial available for temozolomide and Bone Cancer
| Article | Year |
|---|---|
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; | 2008 |
18 other studies available for temozolomide and Bone Cancer
| Article | Year |
|---|---|
Intensive Multimodal Therapy Combined With Long-term Temozolomide and Etoposide Treatment for Recurrent Osteosarcoma to the Liver and Stomach.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined Modality Therapy; Et | 2022 |
Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Dacarbazine; Hu | 2023 |
Individualized combination therapies based on whole-exome sequencing displayed significant clinical benefits in a glioblastoma patient with secondary osteosarcoma: case report and genetic characterization.
Topics: Bone Neoplasms; Brain Neoplasms; Everolimus; Exome Sequencing; Female; Glioblastoma; Humans; Middle | 2022 |
Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model.
Topics: Alginates; Animals; Bone Neoplasms; Cell Line, Tumor; Chondrosarcoma; Humans; Poly(ADP-ribose) Polym | 2023 |
Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2020 |
Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Diarrhea; Disease Prog | 2021 |
Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Female; Humans; Irinotecan; M | 2022 |
Irinotecan-induced muscular contractions.
Topics: Abdominal Muscles; Administration, Intravenous; Administration, Oral; Adolescent; Bone Neoplasms; Hu | 2018 |
Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2019 |
Chemotherapy-induced secondary pneumothorax.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizuma | 2014 |
Extraneural metastases of anaplastic oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Neoplasms; Dacarbazine; Humans; Lymphatic M | 2014 |
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Combined Modality Th | 2014 |
Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Line, Tumor; Dacarbazi | 2015 |
Dramatic response to temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma with widespread osseous metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptothecin; Cerebella | 2016 |
Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chemoradiotherapy; Dacarbaz | 2016 |
NK cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Bone Marrow Neoplasms | 2012 |
Successful treatment of a chemoresistant tumor with temozolomide in an adult patient: report of a recurrent intracranial mesenchymal chondrosarcoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Neoplasms; Chondrosarcoma, Mesenchym | 2005 |
Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineop | 2007 |